Literature DB >> 8614844

A computer program to assist in making breast cancer adjuvant therapy decisions.

P M Ravdin1.   

Abstract

This report describes a computer program designed to assist health care professionals in making projections of the average benefit of systemic adjuvant therapy for individual breast cancer patients. It requires as input patient age (used to make projections of natural mortality), an estimate of breast cancer-related mortality at 5 years (used to make projections of breast cancer-specific mortality), and the proportional risk reduction for breast cancer mortality expected for the adjuvant therapy (with included tables from the Early Breast Cancer Trialist's 1992 meta-analysis). The program uses life table analytical techniques to make projections of outcome in three scenarios: that the breast cancer never occurred, that the breast cancer patient received definitive local therapy but no adjuvant systemic therapy, and that the patient received adjuvant therapy. The outcome projections are given for total, natural (non-breast cancer-related), and breast cancer-related mortality at several time points and also of total remaining life expectancy. These estimates are currently widely made by clinicians by nonnumerical techniques. Computer-based tools can serve as valuable aids in physician and patient education and in the process of informed decision making.

Entities:  

Mesh:

Year:  1996        PMID: 8614844

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  11 in total

1.  Nomogram Identifies Age as the Most Important Predictor of Overall Survival in Oral Cavity Squamous Cell Cancer After Primary Surgery.

Authors:  Supriya Gupta; Jennifer Waller; Jimmy Brown; Yolanda Elam; James V Rawson; Darko Pucar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-08-16

2.  Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.

Authors:  Samuel J Wang; Andrew Lemieux; Jayashree Kalpathy-Cramer; Celine B Ord; Gary V Walker; C David Fuller; Jong-Sung Kim; Charles R Thomas
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

Review 3.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Authors:  Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

4.  Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?

Authors:  Jeffrey K Belkora; David W Hutton; Dan H Moore; Laura A Siminoff
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

Review 5.  Molecular Biology in the Breast Clinics-Current status and future perspectives.

Authors:  Vani Parmar; Nita S Nair; Purvi Thakkar; Garvit Chitkara
Journal:  Indian J Surg Oncol       Date:  2019-08-10

6.  External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.

Authors:  David Hajage; Yann de Rycke; Marc Bollet; Alexia Savignoni; Martial Caly; Jean-Yves Pierga; Hugo M Horlings; Marc J Van de Vijver; Anne Vincent-Salomon; Brigitte Sigal-Zafrani; Claire Senechal; Bernard Asselain; Xavier Sastre; Fabien Reyal
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

7.  Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models.

Authors:  E Laas; P Mallon; M Delomenie; V Gardeux; J-Y Pierga; P Cottu; F Lerebours; D Stevens; R Rouzier; F Reyal
Journal:  Br J Cancer       Date:  2015-01-15       Impact factor: 7.640

8.  The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study.

Authors:  Anna M Sawka; David P Goldstein; James D Brierley; Richard W Tsang; Lorne Rotstein; Shereen Ezzat; Sharon Straus; Susan R George; Susan Abbey; Gary Rodin; Mary Ann O'Brien; Amiram Gafni; Lehana Thabane; Jeannette Goguen; Asima Naeem; Lilian Magalhaes
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

9.  Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.

Authors:  Jeffrey K Belkora; Hope S Rugo; Dan H Moore; David W Hutton; Daniel F Chen; Laura J Esserman
Journal:  BMC Cancer       Date:  2009-04-28       Impact factor: 4.430

10.  Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.

Authors:  Molly E Klein; David J Dabbs; Yongli Shuai; Adam M Brufsky; Rachel Jankowitz; Shannon L Puhalla; Rohit Bhargava
Journal:  Mod Pathol       Date:  2013-03-15       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.